Design, synthesis, and bioactivity of newly potent pleuromutilin derivatives.

The overuse of antibiotics has led to the progressively severe issue of bacterial drug resistance. As a result, a large number of antibiotics available on the market show a notably diminished effectiveness against drug-resistant bacteria. Thus, a series of dimethylcysteamine pleuromutilin derivatives were designed and synthesized. Both in vitro and in vivo tests were conducted to evaluate their activities against bacteria. Most derivatives exhibited potent antibacterial effects against Gram - positive bacteria, and their antibacterial activities were superior to those of tiamulin. Derivative 4g showed exceptional antibacterial activity, having MIC values as low as 0.016 μg/mL. Furthermore, compared to tiamulin, it exhibited a significantly longer post-antibiotic effect (PAE) and a slower rate of resistance development. The molecular docking results of derivative 4g were excellent, and it effectively inhibited the expression of green fluorescent protein (GFP) in bacteria. Derivative 4g exhibited extremely low cytotoxicity and had low oral acute toxicity, with an LD50 exceeding 2000 mg/kg of body weight. Derivative 4g demonstrated a more powerful therapeutic impact against MRSA infection compared to tiamulin and valnemulin. Considering these results, derivative 4g stands out as an extremely promising compound, having significant potential for the future development of therapeutic uses.

• Publication year

  2025

• Venue

  European journal of medicinal chemistry

• Publication date

  2025-08-04

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejmech.2025.118037PMID 40763662
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of novel thiazole-pleuromutilin derivatives with potent antibacterial activity.

  2025cited by this paper
• Revisiting the potential of natural products in antimycobacterial therapy: advances in drug discovery and semisynthetic solutions.

  2024cited by this paper
• Recent advances in developing modified C14 side chain pleuromutilins as novel antibacterial agents.

  2024cited by this paper
• Novel pleuromutilin derivatives conjugated with phenyl-sulfide and boron-containing moieties as potent antibacterial agents against antibiotic-resistant bacteria.

  2024cited by this paper
• Multiple antimicrobial and immune-modulating activities of cysteamine in infectious diseases.

  2024cited by this paper
• Design, Synthesis, Biological Evaluation, and Molecular Docking Studies of Pleuromutilin Derivatives Containing Thiazole.

  2024cited by this paper
• Discovery of Novel Coumarin Pleuromutilin Derivatives as Potent Anti-MRSA Agents.

  2024cited by this paper
• Novel pyridinium cationic pleuromutilin analogues overcoming bacterial multidrug resistance.

  2023cited by this paper
• Synthesis and evaluation of novel pleuromutilin derivatives targeting the 50S ribosomal subunit for antibacterial ability.

  2023cited by this paper
• A Review on the Antimutagenic and Anticancer Effects of Cysteamine

  2023cited by this paper
• Pasteurella multocida causes liver injury in ducks by mediating inflammatory, apoptotic and autophagic pathways.

  2023cited by this paper
• Streptococcus agalactiae virulence factors isolated from bovine mastitis and antibiotic treatment response.

  2023cited by this paper
• Design, Synthesis, and Biological Activity of Thioguanine-Modified Pleuromutilin Derivatives.

  2023cited by this paper
• Antibiotic resistance and drug modification: Synthesis, characterization and bioactivity of newly modified potent pleuromutilin derivatives with a substituted piperazine moiety.

  2023cited by this paper
• Design, synthesis and antibacterial activity of novel pleuromutilin derivatives with thieno[2,3-d]pyrimidine substitution.

  2022cited by this paper
• Florfenicol-Polyarginine Conjugates Exhibit Promising Antibacterial Activity Against Resistant Strains

  2022cited by this paper
• Semisynthetic pleuromutilin antimicrobials with therapeutic potential against methicillin-resistant Staphylococcus aureus by targeting 50S ribosomal subunit.

  2022cited by this paper
• Design, synthesis and antibacterial activity evaluation of pleuromutilin derivatives according to twin drug theory

  2021cited by this paper
• Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin

  2021cited by this paper
• Design, synthesis and biological evaluation of pleuromutilin-Schiff base hybrids as potent anti-MRSA agents in vitro and in vivo.

  2021cited by this paper
• Rational design of a new antibiotic class for drug-resistant infections

  2021cited by this paper
• A synthetic antibiotic class overcoming bacterial multidrug resistance

  2021cited by this paper
• Antibacterial properties and clinical potential of pleuromutilins.

  2019cited by this paper
• From Phenylthiazoles to Phenylpyrazoles: Broadening the Antibacterial Spectrum towards Carbapenem-Resistant Bacteria.

  2019cited by this paper
• Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial.

  2019cited by this paper
• Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis

  2019cited by this paper
• Synthesis and Antibacterial Activity Against MRSA of Pleuromutilin Derivatives Possessing a Mercaptoethylamine Linker.

  2018cited by this paper
• Cysteamine revisited: repair of arginine to cysteine mutations

  2017cited by this paper
• Pleuromutilins: Potent Drugs for Resistant Bugs-Mode of Action and Resistance.

  2017cited by this paper
• Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.

  2017cited by this paper
• Natural Products as Sources of New Drugs from 1981 to 2014.

  2016cited by this paper
• Vinardo: A Scoring Function Based on Autodock Vina Improves Scoring, Docking, and Virtual Screening

  2016cited by this paper
• Antibiotics in the clinical pipeline at the end of 2015

  2016cited by this paper
• Antibacterial drug discovery in the resistance era

  2016cited by this paper
• Population pharmacokinetics of valnemulin in swine.

  2014cited by this paper
• In Vitro and in Vivo Metabolite Profiling of Valnemulin Using Ultraperformance Liquid Chromatography–Quadrupole/Time-of-Flight Hybrid Mass Spectrometry

  2014cited by this paper
• Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.

  2014cited by this paper
• Newer antibacterial drugs for a new century

  2010cited by this paper
• AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

  2009cited by this paper
• Performance standards for antimicrobial susceptibility testing

  2001cited by this paper
• Antibiotic Substances From Basidiomycetes: VIII. Pleurotus Multilus (Fr.) Sacc. and Pleurotus Passeckerianus Pilat.

  1951cited by this paper

• Acute and 28-Day Toxicity Evaluation of New Pleuromutilin Derivative 4g.

  2026cites this paper
• Synthesis and biological activity evaluation of a novel pleuromutilin derivative 22-((2-methyl-1-(1H-pyrrole-2-carboxamido)propan-2-yl)thio)-deoxypleuromutilin

  2025cites this paper
• Conformationally restricted pleuromutilins via a pyridinyl-amide tether bias peptidyl transferase center engagement enabling broad-spectrum potency against multidrug-resistant bacteria.

  2025cites this paper